Skip links

UAGC-CS understands that the medical insurance billing process can be a challenge. UAGC-CS is committed in assisting every patient with this process. For your convenience UAGC-CS will assist with obtaining the prior authorization, submitting the claim to the insurance carrier and providing follow up.

The Process Steps

  1. Each sample submitted for testing must be accompanied by a completed requisition form, copy of the front and back of the patient’s insurance card, and a completed ABN form (for Medicare patients that have not met specific testing criteria). Fax to (520) 626-7701 Attn: Gina, Clinical Services Coordinator.
  2. Patient’s benefit eligibility will be verified and authorization will be obtained from the insurance prior to processing the sample. All tests not authorized by the patient’s insurance will be the responsibility of the patient.
  3. Expected time frame for receiving results begins after testing has been approved by the insurance company and/or patient.

Gina Delgado – Clinical Coordinator

1657 E. Helen Street
Keating Building room 124F
Tucson, Arizona 85721

Phone: (520) 626-5002

Fax: (520) 626-7701

Clinic Exome Sequencing:

Test Description CPT
Exome (eg, unexplained constitutional or heritable disorder or syndrome); sequence analysis 81415
Exome (eg, unexplained constitutional or heritable disorder or syndrome); sequence analysis, each comparator exome (eg, parents, siblings) 81416
Exome (eg, unexplained constitutional or heritable disorder or syndrome); re-evaluation of previously obtained exome sequence (eg, updated knowledge or unrelated condition/syndrome) 81417

Prosigna Breast Cancer Prognostic Gene Signature Assay:

Test Description CPT
Oncology (breast), mRNA analysis of 58 genes using hybrid capture, on formalin-fixed paraffin-embedded (FFPE) tissue, prognostic algorithm reported as a risk score 0008M

Solid Tumor Gene Panel

Test Description CPT
Targeted genomic sequence analysis panel, solid organ neoplasm, DNA analysis, and RNA analysis when performed, 5-50 genes (eg, ALK, BRAF, CDKN2A, EGFR, ERBB2, KIT, KRAS, NRAS, MET, PDGFRA, PDGFRB, PGR, PIK3CA, PTEN, RET), interrogation for sequence variants and copy number variants or rearrangements, if performed 81445
Targeted genomic sequence analysis panel, hematolymphoid neoplasm or disorder, DNA analysis, and RNA analysis when performed, 5-50 genes (eg, BRAF, CEBPA, DNMT3A, EZH2, FLT3, IDH1, IDH2, JAK2, KRAS, KIT, MLL, NRAS, NPM1, NOTCH1), interrogation for sequence variants, and copy number variants or rearrangements, or isoform expression or mRNA expression levels, if performed 81450
Targeted genomic sequence analysis panel, solid organ or hematolymphoid neoplasm, DNA analysis, and RNA analysis when performed, 51 or greater genes (eg, ALK, BRAF, CDKN2A, CEBPA, DNMT3A, EGFR, ERBB2, EZH2, FLT3, IDH1, IDH2, JAK2, KIT, KRAS, MLL, NPM1, NRAS, MET, NOTCH1, PDGFRA, PDGFRB, PGR, PIK3CA, PTEN, RET), interrogation for sequence variants and copy number variants or rearrangements, if performed 81455